Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun;71(6):1229-1231.
doi: 10.1136/gutjnl-2021-325238. Epub 2021 Aug 2.

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study

Gilaad G Kaplan #  1 , Christopher Ma #  2 , Carmen Charlton  3   4   5 , Jamil N Kanji  4   6   7 , Graham Tipples  4   5   8 , Nastaran Sharifi  2 , Michelle Herauf  2 , Stephanie Coward  2 , Richard J M Ingram  2 , Lindsay Hracs  2 , Eric I Benchimol  9 , Remo Panaccione  2
Affiliations
Comment

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study

Gilaad G Kaplan et al. Gut. 2022 Jun.
No abstract available

Keywords: COVID-19; IBD.

PubMed Disclaimer

Conflict of interest statement

Competing interests: GGK has received honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer, Amgen and Takeda. He has received research support from Ferring, Janssen, Abbvie, GlaxoSmith Kline, Merck and Shire. He has been a consultant for Gilead. He shares ownership of a patent: treatment of inflammatory disorders, autoimmune disease, and PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 September 2018. CM has received consulting fees from AbbVie, Amgen, AVIR Pharma Inc, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pfizer, Roche and Alimentiv (formerly Robarts Clinical Trials Inc); speaker's fees from AbbVie, AVIR Pharma Inc, Janssen, Takeda and Pfizer; research support from Pfizer. RP has received consulting fees from: AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmith Kline, Janssen, Merck, Mylan, Oppilan Pandion, Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics,Theravance Biopharma, UCB and Takeda Pharmaceuticals; speaker fees from: AbbVie, Arena Pharmaceuticals, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire and Takeda Pharmaceuticals; advisory board: AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance Biopharma and Takeda Pharmaceuticals; research/educational support: AbbVie, Ferring, Janssen, Pfizer and Takeda. EIB has acted as a legal consultant for Hoffman La-Roche Limited and Peabody & Arnold LLP for matters unrelated to a medication used to treat IBD. CC, JNK, GT, NS, Ms Van Huyssteen, SC, Dr Hracs and RJMI: none.

Figures

Figure 1
Figure 1
The proportion of individuals with IBD who mounted an antibody response (A) Among those undergoing serosurveillance and (B) following infection with SARS-CoV-2. All clinical and serological data from this study are available open access on an online interactive dashboard: https://sc-epi.shinyapps.io/COVID_Serology/.
See this image and copyright information in PMC

Comment on

  • Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
    Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22. Gut. 2021. PMID: 33753421

References

    1. Kennedy NA, Goodhand JR, Bewshea C, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 2021;70:865–75. 10.1136/gutjnl-2021-324388 - DOI - PubMed
    1. Padoan A, Bonfante F, Pagliari M, et al. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine 2020;62:103101. 10.1016/j.ebiom.2020.103101 - DOI - PMC - PubMed
    1. Charlton CL, Nguyen L, Bailey A. Pre-Vaccine positivity of SARS-CoV-2 antibodies in Alberta, Canada during the first two waves of the COVID-19 pandemic. Submitted for Publication. mBio 2021. - PMC - PubMed
    1. Gubatan J, Levitte S, Balabanis T, et al. SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in northern California. Gastroenterology 2020;159:1141–4. 10.1053/j.gastro.2020.05.009 - DOI - PMC - PubMed
    1. Berte’ R, Mazza S, Stefanucci MR, et al. Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy. J Crohns Colitis 2021;15:864–8. 10.1093/ecco-jcc/jjaa237 - DOI - PMC - PubMed

Substances